In addition to providing mechanistic understanding of the consequences of STAG2 loss for the transcriptome of Ewing sarcoma cells, our results identified a gene signature that could be further refined to select biomarkers useful for predicting disease progression and/or serve as therapeutic targets. This evidence concerns the gene STAG2 and Ewing sarcoma.